Literature DB >> 6145143

Enzyme defect in a case of tyrosinemia type I, acute form.

N Furukawa, A Kinugasa, T Seo, T Ishii, T Ota, Y Machida, F Inoue, S Imashuku, T Kusunoki, T Takamatsu.   

Abstract

We determined the activities of tyrosine aminotransferase (TAT, EC 2.6.1.5), p-hydroxyphenylpyruvate oxidase (p- HPPA oxidase, EC 1.14.2.2) and fumarylacetoacetate fumarylhydrolase ( FAH , EC 3.7.12) in cytosol of the liver and kidney tissues obtained at autopsy from a case of hereditary tyrosinemia type I. Values were compared with those from a control group of autopsied tissues from three adults and six children, who had died of other causes. In tyrosinemia, these three hepatic enzyme activities were all decreased: TAT showed approximately 35%, p- HPPA oxidase 11%, and FAH 60% of the corresponding control values. On the other hand, kidney enzymes in tyrosinemia revealed that FAH was most significantly decreased to approximately 14% of the control activity. Km values for substrate--determined for p- HPPA oxidase and FAH --were not different between the patient and controls, suggesting no altered properties of these enzymes. We conclude that in the present case of hereditary tyrosinemia type I, the activities of p- HPPA oxidase in liver and FAH in kidney were most strikingly affected. This fact may in part explain the deteriorated metabolism of tyrosine observed in this patient.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6145143     DOI: 10.1203/00006450-198405000-00014

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  2 in total

1.  Persistent succinylacetone excretion after liver transplantation in a patient with hereditary tyrosinaemia type I.

Authors:  M Tuchman; D K Freese; H L Sharp; C B Whitley; M L Ramnaraine; R A Ulstrom; J S Najarian; N Ascher; N R Buist; A B Terry
Journal:  J Inherit Metab Dis       Date:  1985       Impact factor: 4.982

2.  Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I).

Authors:  R M Tanguay; J P Valet; A Lescault; J L Duband; C Laberge; F Lettre; M Plante
Journal:  Am J Hum Genet       Date:  1990-08       Impact factor: 11.025

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.